i will post only this time and disappear....so goodbye & read this one before you get excessively exited... ;-)

San Diego-based Acadia Pharmaceuticals stock price collapsed today on news that its drug for psychosis related to Parkinson’s disease failed in a late-stage clinical trial. It’s a big setback for the small firm because it has no products on the market, and the Parkinson’s drug was the candidate furthest along in its development pipeline.

The company (NASDAQ:ACAD) reported this morning that its experimental drug, pimavanserin, was unable to significantly reduce the number of hallucinations and delusions associated with Parkinson’s disease when compared with a placebo in a study of 298 patients. While two groups in the trial that were treated with pimavanserin showed a reduction in psychotic events, there was also an “unexpected” reduction in such occurrences in the patients who took placebo, according to the company. Acadia’s stock price lost more than two-thirds of its value on the news, and shares traded as low as $1.87 just before noon Eastern time.

As Denise wrote back in May, Acadia had been hoping to silence its critics on Wall Street by reporting positive results in this trial.